Listing 8.09 Chronic Skin Conditions in 2026: How SSA Now Evaluates Dermatitis, Psoriasis, Hidradenitis Suppurativa, and Bullous Disease Under One Rule, and What the Three-Month Treatment Rule Actually Requires

By Anthony Albert, Benefits Research Director, Disability Exchange · Published July 15, 2026

If you filed an SSDI claim for a skin condition three years ago, your attorney was probably reading Listing 8.05 (dermatitis) or Listing 8.06 (hidradenitis suppurativa) as separate rules with their own criteria. Those listings don't exist anymore. SSA reserved them. Same story for 8.02 (ichthyosis), 8.03 (bullous disease), and 8.04 (chronic infections). Every one of those separate categories now flows into a single consolidated rule: Listing 8.09, Chronic Conditions of the Skin or Mucous Membranes.

This isn't a minor edit. It changes what you have to prove, how DDS reads your file, and what documentation package actually meets the listing. If you have severe psoriasis, treatment-resistant eczema, stage III hidradenitis suppurativa, epidermolysis bullosa, chronic skin infections from diabetes, or any of the other conditions the old separate listings used to cover, you're now under 8.09 whether you know it or not. Understanding the new rule is the difference between an approval and a denial that gets appealed for two years.

The exact 2026 rule

Here's Listing 8.09 in the current Blue Book, word for word:

8.09 Chronic conditions of the skin or mucous membranes (see 8.00G) resulting in:

A. Chronic skin lesions or contractures causing chronic pain or other physical limitation(s) that persist despite adherence to prescribed medical treatment for 3 months.

AND

B. Impairment-related functional limitations demonstrated by 1, 2, 3, or 4:

1. Inability to use both upper extremities to the extent that neither can be used to independently initiate, sustain, and complete work-related activities involving fine and gross movements due to chronic skin lesions or contractures; or
2. Inability to use one upper extremity to independently initiate, sustain, and complete work-related activities involving fine and gross movements due to chronic skin lesions or contractures, and a documented medical need for an assistive device that requires the use of the other upper extremity; or
3. Inability to stand up from a seated position and maintain an upright position to the extent needed to independently initiate, sustain, and complete work-related activities due to chronic skin lesions or contractures affecting at least two extremities (including when the limitations are due to involvement of the perineum or the inguinal region); or
4. Inability to maintain an upright position while standing or walking to the extent needed to independently initiate, sustain, and complete work-related activities due to chronic skin lesions or contractures affecting both lower extremities (including when the limitations are due to involvement of the perineum or the inguinal region).

Two parts. Both required. This is the whole test. Prong A is the persistence-despite-treatment prong. Prong B is the functional-limitation prong.

What conditions are now under 8.09

SSA lists these examples in section 8.00G:

• Dermatitis (atopic dermatitis, contact dermatitis, seborrheic dermatitis, nummular eczema)
• Psoriasis (plaque psoriasis, guttate, inverse, pustular, erythrodermic)
• Hidradenitis suppurativa (all Hurley stages, though Stage II and III are the realistic 8.09 candidates)
• Ichthyosis (all subtypes, including lamellar, harlequin, and Netherton syndrome)
• Bullous diseases (pemphigus vulgaris, bullous pemphigoid, epidermolysis bullosa, dermatitis herpetiformis)
• Chronic skin infections (fungal, bacterial, viral, mycobacterial that persist and cause functional limitation)

If you have a chronic skin disorder that isn't specifically named, 8.00I lets DDS still consider it under 8.09 if it fits the pattern (chronic, treatment-resistant, functionally limiting).

Skin manifestations of immune system disorders (lupus, scleroderma, psoriatic arthritis, HIV) are not evaluated under 8.09. Section 8.00H tells adjudicators to send those to Section 14.00 for evaluation under the immune system listings. Same rule for diabetic skin complications with soft tissue involvement or amputation (they go to Section 1.00, musculoskeletal).

Prong A: chronic skin lesions or contractures persisting 3 months on treatment

Let's break Prong A into pieces.

Chronic skin lesions are defined in 8.00B2: lesions that can have recurrent exacerbations and can occur despite prescribed medical treatment. They can be anywhere on your body. SSA specifically calls out the axilla, perineum, inguinal region, palms, soles, upper extremities, and lower extremities because those locations tend to interfere most with movement and daily activities.

Contractures are permanent fibrous scar tissue in the skin that prevents normal movement of the damaged area. Contractures are common in burns (evaluated under 8.08), late-stage epidermolysis bullosa, and long-term hidradenitis suppurativa with tunneling and sinus tracts.

"Persist despite adherence to prescribed medical treatment for 3 months" is spelled out in 8.00D5b. You must have taken the prescribed medications or followed other treatment prescribed by a medical source for 3 consecutive months. The lesions or contractures must still be present, still symptomatic, and still causing functional limitation at the end of that 3-month window. Skin flares that resolve inside 3 months don't count. Neither does a claim filed before you've completed 3 months of documented treatment.

The 3-month treatment window must fall within the 12-month duration period SSA uses to evaluate severity. In practice this means: your treatment history has to show at least 3 months of adherence, and your overall disability has to be expected to last (or actually have lasted) at least 12 months.

Special deferral rule for PUVA and biologics. If you start PUVA (psoralen plus UV-A light) therapy or a biologic like adalimumab, secukinumab, ixekizumab, risankizumab, guselkumab, brodalumab, or bimekizumab, SSA will defer adjudication of your claim for 6 months from the start of that treatment (unless they can make a fully favorable decision on other grounds). This is to see whether the biologic works. If it does, your claim gets denied at 6 months. If it doesn't and you still meet 8.09, you get approved. This deferral rule catches a lot of dermatology and rheumatology patients off guard.

Prong B: functional limitation demonstrated by one of four paths

Prong B is where most claims live or die. You have to fit into one of four boxes.

Path B1: Both upper extremities unusable for fine and gross movements. Fine movements involve wrists, hands, and fingers (picking, pinching, manipulating, fingering). Gross movements involve shoulders, upper arms, forearms, and hands (handling, gripping, grasping, holding, turning, reaching, lifting, carrying, pushing, pulling). If your palms, wrists, elbows, or axillae have lesions or contractures severe enough that both hands are effectively out of service, you're on Path B1.

Path B2: One upper extremity unusable + documented medical need for an assistive device requiring the other UE. This path is for cases where lower extremity or axial disease forces you to use a walker, forearm crutch, or rollator (which needs one working UE), and your other UE is knocked out by skin disease.

Path B3: Cannot rise from seated and maintain upright, due to lesions/contractures affecting at least two extremities (including perineum or inguinal involvement). Severe inguinal or perineal HS, severe genital psoriasis, or lesions affecting both legs plus another site can meet this. The key words are "at least two extremities" and "perineum or inguinal region counts."

Path B4: Cannot maintain upright while standing or walking, due to lesions/contractures affecting both lower extremities (perineum/inguinal counts). Both lower extremities have to be involved. Bilateral severe plantar psoriasis, bilateral pretibial HS with active sinus tracts, or severe bilateral leg ichthyosis with fissures could meet this.

You need to hit exactly one path. Not partial credit across paths. And your treating dermatologist, PCP, or specialist has to document the specific functional impact in a way that maps to the language in the listing.

What documentation you need

Under section 8.00C, DDS wants:

• Diagnosis from an acceptable medical source who has examined you (dermatologist, PCP, or specialist)
• Onset, duration, and frequency of exacerbations
• Prognosis
• Location, size, and appearance of lesions and contractures
• Family history if relevant
• Exposure to toxins, allergens, irritants, seasonal variation, stress factors
• Laboratory findings including biopsies (they won't purchase genetic testing but will use existing results)
• Statements about your restrictions and daily activities

Specifically for prong A, get:

• Complete pharmacy fill history showing 3+ months of continuous prescribed treatment
• Clinic notes at intervals confirming lesions still present after treatment
• Photos of lesions dated across the treatment window (many dermatology charts already capture these)
• Biopsy pathology if available

For prong B, get:

• Physical therapy or occupational therapy notes documenting specific functional limits
• Detailed clinic notes describing which movements are limited and why
• Documented medical need letter for any assistive device you use (walker, forearm crutches, cane), covering at least 12 months
• Objective range of motion measurements if contractures are involved

Worked case 1: severe treatment-resistant psoriasis with palmoplantar involvement

Marisol is 47 years old. She works from home in California. Diagnosis at age 22: plaque psoriasis. Progression to palmoplantar pustular psoriasis by age 40. By 2024 she has chronic thick fissured plaques on both palms, both soles, both elbows, both knees, and scattered on the trunk. She can't grip a knife handle without her palms cracking and bleeding. She can't stand for more than 20 minutes because her soles fissure to bleeding. She's tried methotrexate (elevated LFTs, stopped), cyclosporine (BP issues, stopped), topical clobetasol (partial control), acitretin (poor response), adalimumab (worked initially then failed), and ixekizumab (partial response). She's now on bimekizumab.

Timeline: Started bimekizumab in June 2025. At 6 months of therapy (Dec 2025), palmoplantar disease still active. Dermatology notes describe deep fissures on both palms preventing grip and both soles preventing standing beyond 20 minutes. Files SSDI Jan 2026.

DDS review: Because she started a biologic, SSA deferred adjudication 6 months from bimekizumab start (June 2025 to Dec 2025). At the December review, dermatology documented persistent palmoplantar involvement. Prong A cleared. For prong B, dermatology and OT together documented inability to use both upper extremities for fine and gross movements (Path B1). Approved on 8.09 in Feb 2026.

Why this worked: Long treatment history documented, biologics tried and partially failed with objective evidence, functional impact mapped exactly onto Path B1, treating dermatologist specifically wrote that Marisol could not grip small objects or hold larger objects reliably due to palm fissures.

Worked case 2: Hurley Stage III hidradenitis suppurativa with bilateral inguinal and perineal involvement

Devon is 34 years old, lives in Georgia. HS diagnosis at age 19, progression to Hurley Stage III by 28. Multiple surgical debridements, wide excisions in both axillae and both inguinal regions. Persistent sinus tracts and active drainage in the perineum and both inguinal folds despite treatment. Currently on adalimumab plus doxycycline plus zinc supplementation plus clindamycin/rifampin rotation. Sitting causes drainage. Walking causes wound reopening in the groin folds. Perineal involvement means using the toilet reopens tracts.

Timeline: Adalimumab started March 2025. Full treatment history goes back years. At 3 months of adalimumab (June 2025), disease still active. Continued through 12 months with persistent perineal and bilateral inguinal disease. Files SSDI July 2026.

DDS review: Prong A met (multi-year documented treatment history including biologic for over 12 months, disease persists). For prong B, adjudicator maps case to Path B3: cannot rise from seated and maintain upright, because perineal and inguinal disease affects at least two extremities per the special counting rule in the listing (perineum and inguinal region are treated as counting toward the two-extremity requirement). Approved on 8.09 in November 2026.

Why this worked: The treating dermatologist specifically documented that Devon could not maintain a seated-to-standing transition without reopening perineal wounds. The chart mentioned Hurley stage and cited both inguinal and perineal involvement. Path B3 language was used almost verbatim in one clinic note (this matters more than most people realize).

Common denial reasons and how to counter them

Denial: "Not chronic enough." SSA wants documented lesions across at least 3 months of adherent treatment. If your file only shows 6 weeks of treatment records, DDS will say the 3-month persistence isn't established. Counter by pulling all pharmacy fill records, all clinic notes across the last 12 months, and photos with dates. Reopen with the full paper trail.

Denial: "Treatment response not fully evaluated." If you started a biologic or PUVA recently, DDS applies the 6-month deferral. This isn't a real denial, it's a hold. Wait out the 6 months, then have your dermatologist document persistent disease and refile.

Denial: "Functional limitation not documented." This is the most common. You have lesions but the file doesn't show which specific work-related activities are limited. Counter by requesting an OT functional capacity evaluation focused on the four Prong B paths, and by asking your dermatologist to write a supplemental letter mapping your limits to the listing language.

Denial: "Perineum/inguinal not two extremities." Some adjudicators still miss the special counting rule in Paths B3 and B4. If your denial says perineum or inguinal region alone doesn't count as two extremities, cite 8.09 B3 and B4 directly (they explicitly say "including when the limitations are due to involvement of the perineum or the inguinal region"). This is a common enough mistake that it's worth appealing.

Alternate paths if 8.09 doesn't fit

Section 14.00 immune listings. If your skin disease is a manifestation of psoriatic arthritis, lupus, or systemic sclerosis, 14.09 (inflammatory arthritis), 14.02 (SLE), or 14.04 (systemic sclerosis) applies instead. HIV-related skin conditions go to 14.11.

Listing 8.07 for genetic photosensitivity disorders. Xeroderma pigmentosum and related conditions with abnormal DNA repair are evaluated separately.

Listing 8.08 for burns. Burns that have reached maximum therapeutic benefit and result in chronic lesions or contractures with functional limitation.

Medical-vocational allowance. If you can't meet 8.09 but your skin condition plus age, education, and past work profile means no jobs exist you can perform, you can still get approved outside the listings. This route is harder and slower but real.

What changed and why it matters for pending claims

If your claim was filed under the old separate listings (8.02 through 8.06) and is still pending, DDS will re-evaluate under 8.09. In most cases this is actually favorable because 8.09 covers the same conditions with clearer functional criteria. But your file may have been built around the old rules. Consider having your attorney or your treating specialist add a supplemental letter that maps your limits explicitly to the new 8.09 language.

If you were denied under one of the old listings before the consolidation, and you're still within the 60-day appeal window, appeal under 8.09 and reframe the medical evidence around the new criteria. If you're past the appeal window, you may need to refile.

Frequently asked questions

Is dermatitis by itself enough to qualify for SSDI?

No. You need a chronic skin condition that has persisted 3+ months on prescribed treatment and one of the four functional limitations in Prong B. Mild-to-moderate dermatitis that clears with topical steroids or that doesn't affect movement doesn't meet 8.09. You need documented severe treatment-resistant disease plus a listed functional limit.

How does hidradenitis suppurativa qualify under 8.09?

HS most often qualifies under Path B3 or B4, where perineal or bilateral inguinal involvement counts toward the two-extremity requirement. Hurley Stage II and III with active sinus tracts, tunneling, or persistent drainage that has failed 3+ months of prescribed treatment (biologics, antibiotics, or surgical management) can meet the listing.

Does starting a biologic hurt my claim?

It delays your claim by 6 months but doesn't hurt it if the biologic doesn't work. SSA's 6-month deferral rule exists specifically because biologics can turn severe disease around, so DDS wants to see the outcome before deciding. If the biologic partially works but you still have listed-level lesions and functional limits at 6 months, you can still be approved.

What if I can't afford treatment?

Section 8.00D6 covers this. If you have no ongoing treatment because of access or financial barriers, DDS can still evaluate your case based on the medical record and current evidence alone, or they may schedule a consultative examination. Lack of treatment doesn't automatically kill your claim, but it makes it harder.

Do photos of my skin help?

Yes. Dated clinical photos, dermatology chart photos, and even patient-taken photos with timestamps help establish chronicity and severity. Photos alone aren't sufficient, but combined with the medical record they carry weight.

What if my psoriasis is in multiple body areas but not disabling in any one area?

Prong B is site-specific. Widespread mild-to-moderate psoriasis without a specific functional limitation from any single area probably won't meet 8.09. You need to identify which area or areas produce the listed functional limit and document it clearly. If no single functional path is met, consider a medical-vocational allowance route.

What's the difference between Listing 8.09 and Listing 8.08?

Listing 8.08 is for burns that have reached maximum therapeutic benefit and are no longer under active surgical management. Listing 8.09 is for chronic non-burn skin conditions with the 3-month treatment persistence rule. Both use the same four functional-limitation paths in Prong B.

Bottom line for 2026

The old Blue Book split skin conditions into separate rules for dermatitis, HS, psoriasis-adjacent bullous disease, and chronic infections. That's gone. Listing 8.09 now handles almost all chronic non-burn skin conditions with one clean two-prong rule: persistence despite 3 months of treatment, plus one of four functional limitations. Get the paper trail on both prongs, map your case to a specific path in Prong B, and 8.09 is one of the more predictable listings in the current book.

If you have severe psoriasis, treatment-resistant dermatitis, Hurley Stage II/III hidradenitis, epidermolysis bullosa, or another chronic skin condition and it's limiting your ability to work, don't let the listing consolidation confuse you or your attorney. The path is clearer than it looks.

Related reading

• Listing 3.07 Bronchiectasis: The Three-Hospitalizations Rule
• Listing 14.03 Systemic Vasculitis: The Two Paths to Approval
• Listing 14.04 Systemic Sclerosis and Scleroderma